Advanced Flower Capital's first quarter as a business development company arrived in the middle of a deliberate reinvention. For its first five years the company lent almost exclusively to state-licensed cannabis operators as a real estate investment trust. Effective January 1, 2026 it converted to an externally managed BDC, adopted the fair-value accounting that goes with that status, and announced it would spread its lending across lower middle-market companies in any industry, with cannabis no longer the primary focus. The quarter itself was clean: net investment income of $0.21 a share handily covered a dividend that had been cut to a token $0.05, and net asset value per share rose to $7.90. The market has priced none of that optimism in.
The stock trades near $2.75, roughly 35% of the $7.90 NAV - a discount of about 65%. That is not a mispricing of the quarter's $0.49-per-share growth in net assets; it is the market pricing the credit book the company is trying to move away from. Three loans sit on nonaccrual status, 23.5% of investments at fair value, including Justice Cannabis, whose facility matured without repayment in May, and Devi Holdings, which is in a court-appointed receivership. The legacy cannabis book carries the marks. The bet is that a BDC structure, a broader mandate, and a repositioned book can close a discount that a 65%-to-NAV gap forces to work double-duty: the gap is either the market's estimate of unrecognized losses on the troubled book, or it is an opportunity the balance sheet's own cash and buyback are trying to monetize. Management launched a $5.0 million buyback at up to $3.50 a share - still nearly 56% below stated NAV - and repurchased 719,780 shares in its first six weeks. The clocks are the same ones this report named in the discount: whether NAV holds while the nonaccrual book is resolved, and whether the $77 million of 5.75% senior notes due May 2027 get refinanced on terms the balance sheet can absorb.